Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.

"Conflicts of interest F Argüelles-Arias has participated in advisory boards and has received financial support to attend scientific meetings from Kern Pharma. M.F. Guerra Veloz, R. Perea Amarillo, L. Castro Laria, B. Maldonado Pérez, D. Chaaro Benallal, and A. Benítez Roldán have received financial support to attend scientific meetings from Kern Pharma. A. Vilches-Arenas, V. Merino, G. Ramírez, M.A. Calleja-Hernández, A. Caunedo Álvarez, and M. Romero Gómez have no conflicts of interest."

"The authors would like to thank Dr Ana Moreno Cerro on behalf of Springer Healthcare Communications, who provided medical writing assistance. Medical writing support was funded by Kern Pharma. Further editing support was provided by Alice Wareham PhD (Aspire Scientific Ltd, Bollington, UK) and funded by Celltrion Healthcare Co, Ltd."